"People are starting to retire, and there isn't that much production of urologists every year; there's about 270 that come out for the whole country," says Richard Harris, MD.
In this interview, Richard Harris, MD, FACS, discusses some of the biggest challenges facing urology practices today, including those with staffing and regulations. Harris is the CEO and President of UroPartners and a practicing urologist in Chicago, Illinois. He was interviewed at the 2022 LUGPA Annual Meeting held in Chicago.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.